SLC5A2 and heart failure: More recently, SGLT2 inhibitors (Gliflozins), oral antidiabetic drugs, have shown significant beneficial effects on the risk of recurrent cardiovascular events in patients with heart failure with or without diabetes [11], becoming part of the recommended pharmacological treatment according to the most recent guidelines on the treatment of heart failure with reduced ejection fraction [12].